WO2017056104A1 - Compositions pharmaceutiques stables de tériflunomide - Google Patents

Compositions pharmaceutiques stables de tériflunomide Download PDF

Info

Publication number
WO2017056104A1
WO2017056104A1 PCT/IN2016/050176 IN2016050176W WO2017056104A1 WO 2017056104 A1 WO2017056104 A1 WO 2017056104A1 IN 2016050176 W IN2016050176 W IN 2016050176W WO 2017056104 A1 WO2017056104 A1 WO 2017056104A1
Authority
WO
WIPO (PCT)
Prior art keywords
teriflunomide
pharmaceutical composition
silicon dioxide
colloidal silicon
composition according
Prior art date
Application number
PCT/IN2016/050176
Other languages
English (en)
Inventor
Satyanarayana VATTIKUTI
Krishna Murthy Bhavanasi
Rami Reddy BHIMAVARAPU
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Publication of WO2017056104A1 publication Critical patent/WO2017056104A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil

Definitions

  • the invention relates to oral pharmaceutical compositions of teriflunomide and process for the preparation of such compositions.
  • Teriflunomide is an oral de novo pyrimidine synthesis inhibitor of the DHO-DH enzyme and is chemically designated as (Z)-2-Cyano-3-hydroxy-but-2-enoic acid-(4- trifluoromethylphenyl)-amide with a molecular formula C 12 H9F3N2O2 and following structural formula:
  • Teriflunomide is commercially available as film-coated tablets for oral administration under the trade name AUBAGIO ® .
  • AUBAGIO tablets contain 7 mg or 14 mg of teriflunomide and lactose monohydrate, corn starch, hydroxypropylcellulose, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate as inactive ingredients.
  • the film coating for the 14 mg tablet is made of hypromellose, titanium dioxide, talc, polyethylene glycol and indigo carmine aluminum lake.
  • the 7 mg tablet film coating includes iron oxide yellow.
  • AUBAGIO ® is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
  • US Patent No. 4,965,276 discloses Teriflunomide use in the treatment of chronic graft- versus-host disease.
  • US Patent No. 5,459,163 and US Patent No. 5,679,709 discloses Teriflunomide compositions useful for the treatment of autoimmune diseases in particular lupus erythematosus.
  • US Patent No. 8,802,735 discloses teriflunomide tablet formulations with improved stability, wherein the said tablet formulation does not contain colloidal silicon dioxide. In few examples, colloidal silicon dioxide is present in an amount of 0.33% of weight of the tablet and the tablets are acidified with colloidal silicon dioxide. Also discloses the pH of the tablet composition from 4.5 to 2.0.
  • PCT publication No. WO2015088380 discloses method for producing teriflunomide tablets comprises sifting teriflunomide and excipients through a sieve with average pore size of 0.14-0.20 mm, stirred until homogeneous, followed by forming the mixture into a tablet at a compression pressure of 15-20 kN / cm and applying film coating.
  • this prior art listed colloidal silicon dioxide as lubricant, the preferred lubricant is magnesium stearate and this prior art is silent regarding the acidification of compositions comprising teriflunomide.
  • the prior art disparaged the lubrication of teriflunomide compositions with colloidal silicon dioxide.
  • the composition has to be acidified if it is lubricated with colloidal silicon dioxide.
  • presence of colloidal silicon dioxide in the un-acidified tablet compositions of teriflunomide leads to the increased formation 2-cyano-N-(4- trifluoromethyl-phenyl)-acetamide or 4-trifluoromethyl-aniline (4-TFMA) compared to teriflunomide tablets containing colloidal silicon dioxide.
  • the prioir art disclosed that it is advangeous to add acidic reacting compound to teriflunomide compositions containing colloidal silicon dioxide or without colloidal silicon dioxide.
  • a pharmaceutical composition comprising tenflunomide or salts thereof and colloidal silicon dioxide.
  • an oral solid dosage form comprising teriflunomide or salts thereof and colloidal silicon dioxide.
  • an oral solid dosage form comprising teriflunomide or salts thereof, colloidal silicon dioxide and an alkalizer.
  • a pharmaceutical composition comprising teriflunomide or salts thereof and colloidal silicon dioxide, wherein the pH of the composition is more than 5.0.
  • a process for preparing a pharmaceutical composition of teriflunomide or salts thereof includes the steps of admixing, granulating and/or coating.
  • composition comprising teriflunomide or salts thereof and colloidal silicon dioxide, wherein the composition is packaged with moisture absorber.
  • an oral solid dosage form comprising teriflunomide or salts thereof and colloidal silicon dioxide, wherein the composition is packaged with moisture absorber.
  • Embodiments of the present invention may include one or more of the following features for example the pharmaceutical composition may further include one or more pharmaceutical acceptable excipients.
  • the pharmaceutical acceptable excipients may include diluent, disintegrant, surfactant, binder, lubricant, glidant, plasticizer, antitacking agent, opacifying agent, sweeteners/taste masking agents, colorants and flavors and the like.
  • the inventors of the present invention have developed non-acidified pharmaceutical compositions comprising teriflunomide or salts thereof, where in the composition is lubricated with colloidal silicon dioxide.
  • the developed compositions do not have the disadvantages mentioned in the prior art due to the presence of colloidal silicon dioxide i.e., increase in 2-cyano-N-( 4-trifluoromethyl-phenyl )-acetamide and formation of 4-TFMA
  • Embodiments of the present invention relate to pharmaceutical compositions of teriflunomide or salts thereof comprising one or more pharmaceutically acceptable excipients.
  • the term 'teriflunomide' is used in broad sense to include not only the teriflunomide per se but also its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof, and also its various crystalline and amorphous forms.
  • the pharmaceutical composition comprises teriflunomide or salts thereof and colloidal silicon dioxide.
  • compositions of teriflunomide or salts thereof comprises about 0.1 to about 10% of colloidal silicon dioxide. Preferably, about 0.3 to about 5%, more preferably, 0.5 to 3%.
  • compositions of teriflunomide or salts thereof is not acidified.
  • compositions of teriflunomide comprises teriflunomide or salts, colloidal silicon dioxide and an alkalizer.
  • Alkalizer includes, but are not limited to, sodium carbonate, calcium carbonate, magnesium carbonate, magnesium hydroxide, magnesium oxide, sodium hydroxide and mixtures thereof.
  • the alkalizer is magnesium oxide.
  • the alkalizer may be present in an amount of 1% to 20% by weight of the composition.
  • pH of the pharmaceutical composition comprising teriflunomide or salts thereof and colloidal silicon dioxide is more than 5.0.
  • the pH of the pharmaceutical composition of teriflunomide or salts thereof is in between 5.5 to 12.0, more preferably, 6 to 10.5.
  • the pharmaceutical composition of teriflunomide or salts thereof is an oral solid dosage from, preferably, tablet.
  • composition of teriflunomide or salts thereof can be prepared by any suitable method known in the art such as direct compression, dry or wet granulation, fluidized bed granulation, melt extrusion, melt granulation, spray coating, freeze drying, spray drying and solution evaporation.
  • the pharmaceutical composition is provided as a tablet, which can be film coated with one or more coating agents.
  • the coating agents may include hypromellose, polyvinyl alcohol, and sodium carboxymethyl cellulose.
  • the pharmaceutical composition of teriflunomide is packed with moisture absorber.
  • the pharmaceutical composition comprising teriflunomide or salts thereof and colloidal silicon dioxide, wherein the pharmaceutical composition contains no more than about 0.5% by weight of 2-cyano-N-(4-trifluoromethyl-phenyl)- acetamide after being stored at about 40° C and 75% relative humidity for about 6 months.
  • the final dosage form is packaged using procedures known in the art.
  • the moisture absorbers include activated carbon, silicas, zeolites, molecular sieves, hydrogels, calcium oxide and diatomaceous earth.
  • the particular moisture - retaining materials used will depend upon the humidity level of the environment. For example, in a very low-humidity environment, a moisture-carrying material such as a hydrogel that partially binds water may be preferred.
  • the moisture absorber can be supplied in the form of a sachet, cartridge or canister.
  • a preferred form is a canister of silica gel, such as SorBitTM (commercially supplied by Sud-Chemie Corporation).
  • Multisorb provides variety of moisture absorbers under trade name of Natrasorb M, Natrasorb S, Natrasorb C, and Hi- dry, which comprise diatomaceous earth, silica gel, calcium oxide and molecular sieve, respectively.
  • the pharmaceutical composition comprising teriflunomide or salts thereof contains no more than about 0.5% of 2-cyano-N-( 4-trifluoromethyl-phenyl )-acetamide after being stored at about 40°C.and about 75% relative humidity for about 3 months.
  • Diluent includes, but are not limited to, powdered cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, lactose, starch, dibasic calcium phosphate, tribasic calcium phosphate, calcium carbonate, dextrates, dextrin, dextrose, kaolin, magnesium carbonate, magnesium oxide, sugars such as sucrose; sugar alcohols such as mannitol, sorbitol, erythritol; and mixtures thereof. Diluent may generally be added to increase the bulk volume of the powder to facilitate granulation or compression. The diluent may be present in an amount ranging from 1 % to 90% by weight of the composition.
  • Disintegrant includes, but are not limited to, croscarmellose sodium, sodium starch glycolate, pregelatinized starch, sodium carboxymethyl cellulose, microcrystalline cellulose, cross-linked polyvinylpyrrolidone, sodium alginate and mixtures thereof.
  • the disintegrant may be present in an amount ranging from 1% to 20% by weight of the composition.
  • Surfactants includes, but are not limited to, anionic, cationic, non-ionic or amphoteric surfactants or those known to the person skilled in the art.
  • the amount of surfactant present in the pharmaceutical composition ranges from about 0.1 % to about 10% by total weight of the composition.
  • Binder includes, but are not limited to, carrageenan, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carbomers, carboxymethylcellulose sodium, dextrin, ethyl cellulose, methylcellulose, shellac, zein, gelatin, polymethacrylates, polyvinyl pyrrolidone, pregelatinized starch, sodium alginate, gums, synthetic resins and the like. Binder may be used as a component of the coat to ensure proper adhesion of the subsequent coats. The binder may be present in an amount ranging from 0.1% to 25% by weight of the composition.
  • Lubricant includes, but are not limited to, metallic stearates such as magnesium stearate, calcium stearate, zinc stearate; stearic acid, hydrogenated vegetable oil, hydrogenated castor oil, glyceryl palmitostearate, glyceryl behenate, polyethylene glycols, corn starch, sodium stearyl fumarate, sodium benzoate, mineral oil, talc, and mixtures thereof.
  • Glidant includes talc, colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, tribasic calcium phosphate; and mixtures thereof.
  • the lubricant and/or glidant may be present in an amount ranging from 0.1% to 10% by weight of the composition.
  • Plasticizer may be used in a coat to increase the flexibility and strength of the layer and includes, but are not limited to, propylene glycol, polyethylene glycol, triethyl citrate, acetyl triethyl citrate, diethyl phthalate, diacetylated monoglyceride, dibutyl phthalate, dibutyl sebacate; or mixtures thereof.
  • the plasticizer may be present in an amount ranging from 0.1 % to 20% by weight of the composition.
  • Anti-tacking agent may be used in a coat to aid bulk build-up and form a smooth surface and includes, but are not limited to, talc, kaolin, finely divided silicon dioxide, glyceryl monostearate, and the like.
  • the anti-tacking agent may be present in an amount ranging from 0.1% to 20% by weight of the composition.
  • Opacifying agent may be used in a coat to prevent photo-degradation and includes, but are not limited to, titanium dioxide, iron oxides, and the like.
  • the opacifying agent may be present in an amount ranging from 0.1% to 10% by weight of the composition.
  • Taste masking agents includes, but are not limited to one or more of polymers, surfactants, sweeteners and flavors.
  • polymers include one or more of cellulose acetate, polymethacrylates, cellulose derivatives such as hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxylethyl cellulose; and the like.
  • Sweeteners includes, but are not limited to saccharides such as aspartame, sugar derivatives. Other examples of sweeteners comprise sodium saccharin; aspartame; sugarless sweeteners, hydrogenated starch hydrolysates, alone or in combination.
  • Flavors includes, but are not limited to citric acid, cinnamon, wintergreen, eucalyptus, spearmint, peppermint, menthol, anise as well as fruit flavors such as apple, pear, peach, vanilla, strawberry, cherry, apricot, orange, watermelon, banana and the like; bean-derived flavors, such as coffee, cocoa and the like or mixtures thereof.
  • teriflunomide lactose monohydrate and corn starch, hydroxy propyl cellulose and microcrystalline cellulose (if present) was lubricated with Sodium starch glycolate type A, colloidal silicon dioxide and magnesium stearate and compressed to form tablets.
  • tablets were film coated using commercially available film coating solutions.
  • teriflunomide, lactose monohydrate, corn starch and magnesium oxide was granulated using hydroxy propyl cellulose dispersion in water as binder.
  • the granules were dried and mixed with microcrystalline cellulose (if present), Sodium starch glycolate type A, colloidal silicon dioxide and magnesium stearate and compressed to form tablets.
  • tablets were film coated using commercially available film coating solutions.
  • Teriflunomide Tablets of example 3 are packed in Alu-Alu blisters and stored at 40°C and 75% RH.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques orales de tériflunomide comprenant du tériflunomide ou des sels de ceux-ci, et du dioxyde de silicium colloïdal. L'invention concerne également un procédé pour la préparation de ces compositions.
PCT/IN2016/050176 2015-09-28 2016-06-09 Compositions pharmaceutiques stables de tériflunomide WO2017056104A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5171CH2015 2015-09-28
IN5171/CHE/2015 2015-09-28

Publications (1)

Publication Number Publication Date
WO2017056104A1 true WO2017056104A1 (fr) 2017-04-06

Family

ID=56686855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2016/050176 WO2017056104A1 (fr) 2015-09-28 2016-06-09 Compositions pharmaceutiques stables de tériflunomide

Country Status (1)

Country Link
WO (1) WO2017056104A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022128156A1 (fr) * 2020-12-15 2022-06-23 Pharmathen S.A. Forme posologique solide à libération immédiate comprenant du tériflunomide et son procédé de préparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965276A (en) 1985-09-27 1990-10-23 Hoechst Aktiengesellschaft Medicaments to combat chronic graft-versus-host diseases
US5459163A (en) 1985-09-27 1995-10-17 Hoechst Aktiengesellschaft Medicament to combat autoimmune diseases
WO2011032929A1 (fr) * 2009-09-18 2011-03-24 Sanofi-Aventis Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée
WO2015077535A2 (fr) * 2013-11-22 2015-05-28 Genzyme Corporation Nouvelles méthodes pour traiter des maladies neurodégénératives
WO2015088380A1 (fr) 2013-12-11 2015-06-18 Общество С Ограниченной Ответственностью "Валента-Интеллект" Procédé de production de cachets de tériflunomide
WO2016079687A1 (fr) * 2014-11-18 2016-05-26 Lupin Limited Composition pharmaceutique orale de tériflunomide

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965276A (en) 1985-09-27 1990-10-23 Hoechst Aktiengesellschaft Medicaments to combat chronic graft-versus-host diseases
US5459163A (en) 1985-09-27 1995-10-17 Hoechst Aktiengesellschaft Medicament to combat autoimmune diseases
US5679709A (en) 1985-09-27 1997-10-21 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases
WO2011032929A1 (fr) * 2009-09-18 2011-03-24 Sanofi-Aventis Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée
US8802735B2 (en) 2009-09-18 2014-08-12 Sanofi (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
WO2015077535A2 (fr) * 2013-11-22 2015-05-28 Genzyme Corporation Nouvelles méthodes pour traiter des maladies neurodégénératives
WO2015088380A1 (fr) 2013-12-11 2015-06-18 Общество С Ограниченной Ответственностью "Валента-Интеллект" Procédé de production de cachets de tériflunomide
WO2016079687A1 (fr) * 2014-11-18 2016-05-26 Lupin Limited Composition pharmaceutique orale de tériflunomide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022128156A1 (fr) * 2020-12-15 2022-06-23 Pharmathen S.A. Forme posologique solide à libération immédiate comprenant du tériflunomide et son procédé de préparation

Similar Documents

Publication Publication Date Title
JP5121229B2 (ja) 安定性の向上した固形製剤およびその製造方法
JP6092936B2 (ja) 口腔内崩壊錠の製造方法
DK2605757T3 (en) Nalbuphine-based formulations and applications thereof
EP2097372B1 (fr) Procédé pour la préparation de la mémantine et de sa forme de sel d'acide chlorhydrique
HU230161B1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient
NO320767B1 (no) Granulat for fremstilling av hurtig desintegrerende og hurtig oppløselige blandinger inneholdende en høy mengde aktiv bestanddel
JPWO2002024166A1 (ja) 崩壊性が良好な経口製剤
EP2815752B1 (fr) Composition pharmaceutique orale
MX2010008711A (es) Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada.
WO2012101653A2 (fr) Compositions pharmaceutiques de mémantine à libération modifiée
JP2018118966A (ja) ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
HUE031251T2 (en) Controlled release oral dosage form containing oxycodone
NZ202140A (en) Delayed release nitrofurantoin tablets
CA2760040A1 (fr) Transformation a sec de retigabine
JP3833314B2 (ja) 発泡性組成物およびその製造方法
WO2016079687A1 (fr) Composition pharmaceutique orale de tériflunomide
WO2005097104A1 (fr) PRÉPARATION PHARMACEUTIQUE SOLIDE CONTENANT UN DÉRIVÉ DE DIBENZ[b,e]OXÉPINE
WO2017056104A1 (fr) Compositions pharmaceutiques stables de tériflunomide
IL293096A (en) A pharmaceutical preparation for oral administration containing a carbamate compound and a method for its preparation
JP5664225B2 (ja) 不快味マスキング粒子及びこれを含有する経口製剤
ES2533956T3 (es) Desfesoterodina en forma de una sal de ácido tartárico
AU2007316588B2 (en) Oral dosage form comprising tri-substituted glycerol compounds
JP5065519B1 (ja) 結晶性アトルバスタチンカルシウム含有錠剤の製造方法
US20160058730A1 (en) Pharmaceutical compositions of teriflunomide
JP2016098187A (ja) 口腔内崩壊錠

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16751670

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16751670

Country of ref document: EP

Kind code of ref document: A1